To evaluate safety and efficacy of Sitagliptinversus Metformin alone and combination in Type 2 Diabetesmellitus

Abstract

Introduction: Type 2 Diabetes mellitus is characterized characterized by insulin resistance, where the body does not fully respond to insulin. Because insulin cannot work properly, blood glucose levels keep rising, releasing more insulin. Material and Methods: This is a Comparative, Prospective, Parallel group, Randomized study. Study was conducted in Type 2DM patients attending at Department of Endocrinology, Sapthagiri Institute of Medical Scinences and Research center over a period of six months. Group I received Metformin 500 mg BD for 3 months, Group II received Sitagliptin 50 mg BD for 3 months and Group III Metformin 500 mg BD and Sitagliptin 50mg BD for 3 months. Result: The mean fasting blood glucose level in Group I at baseline was 148.75±9.54 mg/dl, in Group II was 149.85±8.38 mg/dl and in Group III was 148.47±9.58. The mean fasting blood glucose level in Group I after 3 months was 97.65±7.86 mg/dl, in Group II was 90.65±7.76 mg/dl and in Group III was 83.65±7.75 mg/dl. These was statistically highly significant difference in mean Fasting Blood Glucose level at baseline versus after 3 months in Group I, Group II and Group III (p<0.0001). The mean of HbA1c level was 7.58±0.85% at baseline and 6.94±0.74% after 3rd month. In Group II the mean of HbA1c level was 7.56±0.74 % at baseline, 6.56±0.67 % after 3rd month. In Group III the mean of HbA1c level was 7.59±0.74 % at baseline and 6.38±0.67 % after 3rd month. Conclusion: Sitagliptin with Metformin causes efficient glycaemic control with less significant adverse reaction but the gylcaemic control of patients taking Sitagliptin with Metformin was slightly better as compared to patients taking alone. Thus, concluding Sitagliptin with Metformin to be more efficacious than alone.